Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development (Q28266913)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

2 references

25 October 2022

Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Zoltán Beck

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

George Füst

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

English

0 references

publication date

10 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

6 June 2008

1 reference

25 October 2022

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

25 October 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

3078-3085

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

AIDS vaccine fails in Thai trial

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

HIV vaccine fails in phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

AIDS research. Promising AIDS vaccine's failure leaves field reeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Enhancing antibodies in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Antibody-Dependent Enhancement of Virus Infection and Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

In Vivo Enhancement of Dengue Virus Infection in Rhesus Monkeys by Passively Transferred Antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Pathogenesis of dengue: challenges to molecular biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

A prospective study of dengue infections in Bangkok

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

A new mechanism for the neutralization of enveloped viruses by antiviral antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Complement receptor mediates enhanced flavivirus replication in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Influence of immunological factors in respiratory syncytial virus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Antibody‐Dependent Enhancement, a Possible Mechanism in Augmented Pulmonary Disease of Respiratory Syncytial Virus in the Bonnet Monkey Model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Antibody-dependent enhancement of Ebola virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Immunisation strategies for the management of severe acute respiratory syndrome (SARS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Antibody-dependent enhancement of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Fc receptor but not complement binding is important in antibody protection against HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Mechanism for complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 infection in MT2 cells is enhanced entry through CD4, CD21, and CXCR4 chemokine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Passive immunization of macaques against SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Passive immunization of rhesus macaques against SIV infection and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Lessons from failure--preparing for future HIV-1 vaccine efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.028

7 January 2021

inferred from DOI database lookup

1 reference

12 December 2020

Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease

1 reference

12 December 2020

Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group

1 reference

12 December 2020

Antibody-dependent enhancement of viral infectivity.

1 reference

12 December 2020

[Macaque immunization with virions purified from a primary isolate of the human immunodeficiency virus type 1 induced enhancement antibodies]

1 reference

12 December 2020

Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro

1 reference

12 December 2020

Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release

1 reference

12 December 2020

Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1

1 reference

12 December 2020

Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line

1 reference

12 December 2020

Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro

1 reference

12 December 2020

Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever

1 reference

12 December 2020

10.1016/J.VACCINE.2007.12.028

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

PMC publication ID

7115406

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18241961%20AND%20SRC:MED&resulttype=core&format=json